Impax Asset Management Group plc Sells 964,695 Shares of Boston Scientific Co. (NYSE:BSX)

Impax Asset Management Group plc reduced its stake in Boston Scientific Co. (NYSE:BSX) by 17.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,505,479 shares of the medical equipment provider’s stock after selling 964,695 shares during the period. Boston Scientific makes up 1.8% of Impax Asset Management Group plc’s portfolio, making the stock its 13th largest holding. Impax Asset Management Group plc owned approximately 0.31% of Boston Scientific worth $401,143,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. Crestwood Advisors Group LLC increased its holdings in shares of Boston Scientific by 2.1% in the fourth quarter. Crestwood Advisors Group LLC now owns 67,928 shares of the medical equipment provider’s stock worth $6,067,000 after purchasing an additional 1,397 shares during the last quarter. IFP Advisors Inc increased its stake in Boston Scientific by 17.4% in the 4th quarter. IFP Advisors Inc now owns 8,105 shares of the medical equipment provider’s stock worth $724,000 after acquiring an additional 1,200 shares during the last quarter. Hardman Johnston Global Advisors LLC increased its stake in Boston Scientific by 27.2% in the 4th quarter. Hardman Johnston Global Advisors LLC now owns 326,904 shares of the medical equipment provider’s stock worth $29,199,000 after acquiring an additional 69,910 shares during the last quarter. RWC Asset Management LLP raised its holdings in shares of Boston Scientific by 18.3% during the 4th quarter. RWC Asset Management LLP now owns 3,216 shares of the medical equipment provider’s stock worth $287,000 after acquiring an additional 498 shares in the last quarter. Finally, HealthInvest Partners AB boosted its position in shares of Boston Scientific by 45.3% during the 4th quarter. HealthInvest Partners AB now owns 154,222 shares of the medical equipment provider’s stock valued at $13,831,000 after acquiring an additional 48,050 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.9 %

Shares of NYSE BSX opened at $104.44 on Monday. Boston Scientific Co. has a 52-week low of $65.52 and a 52-week high of $107.17. The firm has a market capitalization of $154.12 billion, a price-to-earnings ratio of 83.55, a PEG ratio of 2.79 and a beta of 0.80. The stock has a 50 day moving average price of $97.98 and a 200 day moving average price of $89.49. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Sell-side analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BSX shares. Canaccord Genuity Group upped their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Raymond James boosted their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Thursday, February 6th. Stifel Nicolaus boosted their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $107.39.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the sale, the executive vice president now owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 139,630 shares of company stock worth $14,467,616 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.